Top Markets
#1 Akedo Akedo +70.80%
#2 MEET48 MEET48 +28.68%
#3 Bitway Bitway +22.15%
#4 Astar Astar +18.51%
#5 VeThor VeThor +16.97%
#6 Falcon Finance Falcon Finance +11.18%
#7 龙虾 (Lobster) 龙虾 (Lobster) +10.89%
#8 Cross Cross +10.81%
#9 Power Protocol Power Protocol +10.32%
#10 AI Rig Complex AI Rig Complex +10.27%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Share Price
$0.25974701
Last synced: 2025-01-06
Market Cap
$2.04M
Change (1 day)
0.74%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Healthcare
Operating Margin for Acticor Biotech SAS (ALACT)
Operating Margin as of September 2026 TTM: 0.00%
According to Acticor Biotech SAS latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2022 the company had an Operating Margin of 0.00%.
Operating Margin history for Acticor Biotech SAS from 2010 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% -100.00%
2018 -11,664.00% 10,383.55%
2017 -111.26% 3,945.82%
2016 -2.75% -75.66%
2015 -11.30% 129.67%
2014 -4.92% -135.55%
2013 13.84% -35.51%
2012 21.46% -9.72%
2011 23.77% 152.07%
2010 9.43% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.